CytoDyn Inc. (CYDY), a clinical-stage oncology company, announced on Tuesday completion of enrolment in the Phase 2 CLOVER trial for Leronlimab in combination with trifluridine and tipiracil plus bevacizumab for treating metastatic colorectal cancer (mCRC).
Leronlimab is a first-in-class monoclonal antibody (mAb) that acts by inhibition of CCR5, modulating the tumor microenvironment to effect an immune response against cancer cells.
The drug is currently being evaluated for the treatment of CCR5-positive, microsatellite stable (MSS), relapsed/refractory metastatic colorectal cancer (mCRC) in the Phase 2 CLOVER open-label, randomized, two-arm, multicenter trial. With 60 patients enrolled, the study will aim to meet a primary endpoint of overall response rate (ORR), and secondary endpoints of safety, tolerability, and overall survival (OS) over a 12-month follow-up period.
The company plans to release topline data from the trial as it becomes available.
CYDY closed Tuesday at $0.37, up 2.78%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.